P21Cip1 Confers resistance to imatinib in human chronic myeloid leukemia cells

Cancer Letters

Volumn 292, Issue 1, 2010, Pages 133-139

  Ferrandiz, Nuria ^a   Caraballo, Juan M ^a   Albajar, Marta ^a,b   Teresa Gomez Casares, M ^c   Lopez Jorge, Carmen E ^c   Blanco, Rosa ^a   Dolores Delgado, M ^a   Leon, Javier ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Apoptosis; Chronic myeloid leukemia; Imatinib; P21

Indexed keywords

BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; IMATINIB; PROTEIN P21; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; DRUG RESPONSE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; G2 PHASE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES;

EID: 77951223635     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.11.017     Document Type: Article

References (44)

1. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
2. Gu Y., Turck C.W., Morgan D.O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993, 366:707-710.
3. Dulic V., Kaufmann W.K., Wilson S.J., Tlsty T.D., Lees E., Harper J.W., Elledge S.J., Reed S.I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994, 76:1013-1023.
4. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707.
5. Brugarolas J., Chandrasekaran C., Gordon J.I., Beach D., Jacks T., Hannon G.J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995, 377:552-557.
6. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995, 82:675-684.
7. Efeyan A., Collado M., Velasco-Miguel S., Serrano M. Genetic dissection of the role of p21Cip1/Waf1 in p53-mediated tumour suppression. Oncogene 2007, 26:1645-1649.
8. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment?. Trends Cell Biol. 2003, 13:65-70.
9. Poole J.C., Thain A., Perkins N.D., Roninson I.B. Induction of transcription by p21Waf1/Cip1/Sdi1: role of NFkappaB and effect of non-steroidal anti-inflammatory drugs. Cell Cycle 2004, 3:931-940.
10. Devgan V., Mammucari C., Millar S.E., Brisken C., Dotto G.P. p21WAF1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation. Genes Dev. 2005, 19:1485-1495.
11. Weiss R.H. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003, 4:425-429.
12. Janicke R.U., Sohn D., Essmann F., Schulze-Osthoff K. The multiple battles fought by anti-apoptotic p21. Cell Cycle 2007, 6:407-413.
13. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 2002, 1:639-649.
14. Ferrandiz N., Martin-Perez J., Blanco R., Donertas D., Weber A., Eilers M., Dotto P., Delgado M.D., Leon J. HCT116 cells deficient in p21(Waf1) are hypersensitive to tyrosine kinase inhibitors and adriamycin through a mechanism unrelated to p21 and dependent on p53. DNA Repair 2009, 8:390-399.
15. Abbas T., Dutta A. p21 in cancer: intricate networks and multiple activities. Nature Rev. 2009, 9:400-414.
16. Martin-Caballero J., Flores J.M., Garcia-Palencia P., Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res. 2001, 61:6234-6238.
17. Philipp J., Vo K., Gurley K.E., Seidel K., Kemp C.J. Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis. Oncogene 1999, 18:4689-4698.
18. Poole A.J., Heap D., Carroll R.E., Tyner A.L. Tumor suppressor functions for the Cdk inhibitor p21 in the mouse colon. Oncogene 2004, 23:8128-8134.
19. Topley G.I., Okuyama R., Gonzales J.G., Conti C., Dotto G.P. p21(WAF1/Cip1) functions as a suppressor of malignant skin tumor formation and a determinant of keratinocyte stem-cell potential. Proc Nat. Acad. Sci. USA 1999, 96:9089-9094.
20. Jackson R.J., Engelman R.W., Coppola D., Cantor A.B., Wharton W., Pledger W.J. p21Cip1 nullizygosity increases tumor metastasis in irradiated mice. Cancer Res. 2003, 63:3021-3025.
21. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 2002, 1:493-502.
22. Druker B.J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002, 1:31-36.
23. Dan S., Naito M., Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death Diff. 1998, 5:710-715.
24. Fang G., Kim C.N., Perkins C.L., Ramadevi N., Winton E., Wittmann S., Bhalla K.N. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000, 96:2246-2253.
25. Gomez-Casares M.T., Vaque J.P., Lemes A., Molero T., Delgado M.D., Leon J. C-myc expression in cell lines derived from chronic myeloid leukemia. Haematologica 2004, 89:241-243.
26. Keeshan K., Mills K.I., Cotter T.G., McKenna S.L. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype. Leukemia 2001, 15:1823-1833.
27. Forster K., Obermeier A., Mitina O., Simon N., Warmuth M., Krause G., Hallek M. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells. Ann. Hematol. 2008, 87:183-193.
28. Pegoraro L., Matera L., Ritz J., Levis A., Palumbo A., Biagini G. Establishment of a Ph1-positive human cell line (BV173). J. Nat. Cancer Inst. 1983, 70:447-453.
29. Beran M., Pisa P., O'Brien S., Kurzrock R., Siciliano M., Cork A., Andersson B.S., Kohli V., Kantarjian H. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res. 1993, 53:3603-3610.
30. Ogura M., Morishima Y., Ohno R., Kato Y., Hirabayashi N., Nagura H., Saito H. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 1985, 66:1384-1392.
31. Lozzio B.B., Lozzio C.B. Properties of the K562 cell line derived from a patient with chronic myeloid leukemia. Int. J. Cancer 1977, 19:136.
32. Munoz-Alonso M.J., Acosta J.C., Richard C., Delgado M.D., Sedivy J., Leon J. p21Cip1 and p27Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells. J. Biol. Chem. 2005, 280:18120-18129.
33. Albajar M., Gutierrez P., Richard C., Rosa-Garrido M., Gomez-Casares M.T., Steegmann J.L., Leon J., Delgado M.D. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Lett. 2008, 270:328-336.
34. Ajenjo N., Canon E., Sanchez-Perez I., Matallanas D., Leon J., Perona R., Crespo P. Subcellular localization determines the protective effects of activated ERK2 against distinct apoptogenic stimuli in myeloid leukemia cells. J. Biol. Chem. 2004, 279:32813-32823.
35. Niculescu A.B., Chen X., Smeets M., Hengst L., Prives C., Reed S.I. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol. 1998, 18:629-643.
36. Schepers H., Geugien M., Eggen B.J., Vellenga E. Constitutive cytoplasmic localization of p21(Waf1/Cip1) affects the apoptotic process in monocytic leukaemia. Leukemia 2003, 17:2113-2121.
37. Keeshan K., Cotter T.G., McKenna S.L. Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway. Brit. J. Haematol. 2003, 123:34-44.
38. Munoz-Alonso M., Leon J. G1 phase control and cell differentiation. G1 Phase Progression 2003, 1-29. Landes Bioscience, New York. J. Boonstra (Ed.).
39. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H.M. The biology of chronic myeloid leukemia. New Eng. J. Med. 1999, 341:164-172.
40. Ceballos E., Delgado M.D., Gutierrez P., Richard C., Muller D., Eilers M., Ehinger M., Gullberg U., Leon J. c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells. Oncogene 2000, 19:2194-2204.
41. Gartel A.L., Tyner A.L. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp. Cell Res. 1999, 246:280-289.
42. Takahashi S., Harigae H., Kaku M., Sasaki T., Licht J.D. Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5. Biochem. Biophys. Res. Commun. 2004, 316:85-92.
43. Shuai K., Halpern J., Ten Hoeve J., Rao X., Sawyers C.L. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996, 13:247-254.
44. de Groot R.P., Raaijmakers J.A., Lammers J.W., Jove R., Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1999, 94:1108-1112.